Article: Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
2004 Volume 11, Issue 2, Page(s) 191–205
Abstract: ... used alone or more likely with other agents, may be the next exciting targeted therapy in breast cancer. ... farnesylation by farnesyl transferase, and inhibitors of this enzyme have been demonstrated to inhibit Ras ... signaling, and have anti-tumor effects. However, it is now clear that farnesyl transferase inhibitors (FTIs ...
| Abstract | The ras family of proto-oncogenes are upstream mediators of several essential cellular signal transduction pathways involved in cell proliferation and survival. Point mutations of ras oncogenes result in constitutively active Ras and have been shown to be oncogenic. However, ras activation can occur in the absence of ras mutations secondary to upstream receptor activation. The first important step in Ras activation is farnesylation by farnesyl transferase, and inhibitors of this enzyme have been demonstrated to inhibit Ras signaling, and have anti-tumor effects. However, it is now clear that farnesyl transferase inhibitors (FTIs) have activity independent of Ras, most likely due to effects on prenylated proteins downstream of Ras, which explains their activity in several malignancies, including breast cancer, where ras mutations are rare. Several FTIs are in clinical development for the treatment of solid tumors. Preclinical evidence suggests that FTIs can inhibit breast cancers in vitro and in vivo, and a phase II trial of the FTI, R115777, in patients with advanced breast cancer produced encouraging results. Based on prior successful outcomes with agents targeting the estrogen and epidermal growth factor receptor pathways in breast cancer, the FTIs, used alone or more likely with other agents, may be the next exciting targeted therapy in breast cancer. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Alkyl and Aryl Transferases/antagonists & inhibitors ; Alkyl and Aryl Transferases/metabolism ; Animals ; Antineoplastic Agents/pharmacology ; Breast Neoplasms/drug therapy ; Breast Neoplasms/enzymology ; Enzyme Inhibitors/pharmacology ; Farnesyltranstransferase ; Female ; Humans | |||||
| Chemical Substances | Antineoplastic Agents ; Enzyme Inhibitors ; Alkyl and Aryl Transferases (EC 2.5.-) ; Farnesyltranstransferase (EC 2.5.1.29) | |||||
| Language | English | |||||
| Publishing date | 2004-05-06 | |||||
| Publishing country | England | |||||
| Document type | Journal Article ; Review | |||||
| ZDB-ID | 1218450-0 | |||||
| ISSN | 1479-6821 ; 1351-0088 | |||||
| ISSN (online) | 1479-6821 | |||||
| ISSN | 1351-0088 | |||||
| DOI | 10.1677/erc.0.0110191 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 4192: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.